Infliximab therapy in Crohn's disease: Safety issues

Netherlands Journal of Medicine

Volumn 61, Issue 4, 2003, Pages 100-104

  Hommes, D W ^a   van Deventer, S J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BCG VACCINE; CHIMERIC ANTIBODY; CLEMASTINE; CORTICOSTEROID; CYTOKINE; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; PLACEBO; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ARTHRALGIA; ASPERGILLOSIS; BIOTECHNOLOGY; CLINICAL IMMUNOLOGY; CLINICAL PRACTICE; CROHN DISEASE; CYTOLYSIS; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DIZZINESS; DOCTOR PATIENT RELATION; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG SAFETY; DYSPHAGIA; DYSPNEA; FACE EDEMA; FEVER; FLUSHING; GLOMERULONEPHRITIS; HAND DISEASE; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPERSENSITIVITY REACTION; INFUSION SITE REACTION; LIP DISEASE; LISTERIOSIS; LUNG TUBERCULOSIS; LUPUS VULGARIS; LYMPHOMA; MACROPHAGE ACTIVATION; MYALGIA; NAUSEA; NEOPLASM; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT EDUCATION; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; POLYARTHRITIS; PRACTICE GUIDELINE; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SIDE EFFECT; SORE THROAT; T LYMPHOCYTE ACTIVATION; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; SAFETY; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; HYPERSENSITIVITY, DELAYED; INFUSIONS, INTRAVENOUS; SAFETY; SERUM SICKNESS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038721755     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. [Letter: see comments]. Lancet 1993;342:173-4.
2. Deventer SJ van. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999;13(suppl 4):3-8.
3. Hommes DW, Deventer SJ van. Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. Curr Opin Clin Nutr Metab Care 2000;3:191-5.
4. Feagan BG. Safety of biologics: current issues and future concerns. Acta Gastroenterol Belg 2001;64:210-4.
5. Minor PD. Mammalian cells and their contaminants. Dev Biol Stand 1996;88:25-9.
6. Deventer SJ van. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
7. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001;7:34-7.
8. Steinberg FM, Raso J. Biotech pharmaceuticals and biotherapy: an overview. J Pharm Pharm Sci 1998;1:48-59.
9. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997;2:33-40.
10. Ohshima S, Mima T, Sasai M, et al. Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA. Cytokine 2000;12;281-8.
11. Hommes DW, Heisteeg BH van de, Spek M van der, Bartelsman JF, Deventer SJ van. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002;8:81-6.
12. Hommes DW, Parlevliet W, Sterringa GJ, Hermans M, Bartelsman JFWM, Deventer SJ van. Infliximab therapy in patients with Crohn's disease; experience with 132 patients. Ned Tijdschr Geneeskd 2002;146:1187-91.
13. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
14. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. [In Process Citation]. Am J Gastroenterol 2000;95:3490-7.
15. Remicade (infliximab) for IV injection. Package Insert Centocor Inc: Melvern, PA, USA, 2002.
16. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254.62.
17. O'Connor M, Buchman A, Marshall G. Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease. Dig Dis Sci 2002;47:1323-5.
18. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 2000;95:2395-6.
19. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-608.
20. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
21. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
22. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's Disease: A user's guide for clinicians. Am J Gastroenterol 2002;97:2962-72.
23. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
24. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002;8:186-91.
25. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002;14:1393-5.
26. Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002;34:410-2.
27. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
28. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol 2000;95:841-2.
29. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112:78.
30. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
31. Salmon D. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002;69:170-2.